Respiratory Medicine
Volume 103, Issue 8 , Pages 1159-1166 , August 2009

Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma

  • Louis-Philippe Boulet

      Affiliations

    • Centre de Recherche, Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval, Québec, QC G1V 4G5, Canada
    • Corresponding Author InformationCorresponding author. Hôpital Laval, 2725 chemin Sainte-Foy, Quebec, QC G1V 4G5, Canada. Tel.: +1 418 656 4747; fax: +1 418 656 4762.
    • ,
  • Catherine Lemière

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Service de Pneumologie, Université de Montréal, Montréal, QC H4J 1C5, Canada
    • ,
  • Gail Gauvreau

      Affiliations

    • Department of Medicine, McMaster University, Medical Center, Hamilton, ON L8N 3Z5, Canada
    • ,
  • Ron Olivenstein

      Affiliations

    • Respiratory Division of the McGill University Health Centre, Montreal, QC H2X 2P4, Canada
    • ,
  • Diane Lougheed

      Affiliations

    • Asthma Research Unit, Clinical Research Centre, Kingston General Hospital, Division of Respirology, Kingston, ON K7L 1O6, Canada
    • ,
  • Bruno Paradis

      Affiliations

    • Centre de Recherche Interdisciplinaire en Réadaptation du Montréal Métropolitain, Jewish Rehabilitation Hospital, Laval, QC H7V 3Y7, Canada
    • ,
  • Paul O'Byrne

      Affiliations

    • Department of Medicine, McMaster University, Medical Center, Hamilton, ON L8N 3Z5, Canada
    • ,
  • René Pageau

      Affiliations

    • Topigen Pharmaceuticals, Montreal, QC H1Y 3N1, Canada
    • Corresponding Author InformationCorresponding author. Research & Development, Topigen Pharmaceuticals Inc., 4050 Molson Street, Room 300, Montreal, QC H1Y 3N1, Canada. Tel.: +1 514 868 0077; fax: +1 514 525 9328.
    • ,
  • Paolo M. Renzi

      Affiliations

    • Topigen Pharmaceuticals, Montreal, QC H1Y 3N1, Canada
    • University of Montreal and Topigen Pharmaceuticals, Montreal, QC H1Y 3N1, Canada

Received 9 September 2008 ,Accepted 15 February 2009.

References 

  1. Barnes PJ. New therapies for asthma. Trends Mol Med. 2006;12:515–520
  2. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995;152:800–803
  3. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, et al. Exhaled Nitric oxide. A predictor of steroid response. Am J Respir Crit Care Med. 2005;172:453–459
  4. Kebir DE, Hubert B, Taha R, Troncy E, Wang T, Gauvin D, et al. Effects of inhaled nitric oxide on inflammation and apoptosis after cardiopulmonary bypass. Chest. 2005;128:2910–2917
  5. Kacmarek RM, Ripple R, Cockrill BA, Bloch KJ, Zapol WM, Johnson DC. Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Am J Respir Crit Care Med. 1996;153:128–135
  6. Högman M, Frostell CG, Hedenström H, Hedenstierna G. Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Respir Dis. 1993;148:1474–1478
  7. Tallet D, Del Soldato P, Oudart N, Burgaud JL. No-steroids:anti-inflammatory drugs with bronchodilating activity in vitro. Biochem Biophys Res Commun. 2002;290:125–130
  8. Nevin BJ, Broadley KJ. Comparative effects of inhaled budesonide and the no-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. Pulm Pharmacol Therapeut. 2004;17:219–232
  9. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174:127–133
  10. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968
  11. LeBlanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy. 2007;62:120–125
  12. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154:308–317
  13. Cockcroft DW. Methacholine challenge. In:  Hargreave FE,  Woolcock AJ editor. Measurement and interpretation. Mississauga, ON: Astra Pharmaceuticals; 1985;p. 22–28
  14. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:976–982
  15. Turner S. The role of exhaled nitric oxide in the diagnosis, management and treatment of asthma. Mini Rev Med Chem. 2007;7:539–542
  16. Duong M, Gauvreau G, Watson R, et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol. 2007;119:322–327
  17. Weiling X, Zheng S, Dweik A, Erzurum SC. Role of epithelial nitric oxide in airway viral infection. Free Radic Biol Med. 2006;41:19–28
  18. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol. 2004;2:820–832
  19. Fang FC. Mechanisms of nitric ocide-related antimicrobial activity. J Clin Invest. 1997;99:2818–2825
  20. Broeke RT, De Crom R, Van Haperen V, Verweij V, Leusink-Muis TA, Van Ark I, et al. Overexpression of endothelial nitric oxide synthase suppresses features of allergic asthma in mice. Respir Res (serial on line). 2006;7:58;Available from http://respiratory-research.com/content/7/1/58
  21. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:171–175
  22. U.S. National Institutes of Health. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. NIH Publication 97:4051:1–153.
  23. Masoli M, Holt S, Weatherhall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur. Respir J. 2004;552–559
  24. Lemière C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, et al. Adult asthma consensus guidelines update 2003. Can Respir J. 2004;11:5A–33A
  25. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118–127
  26. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Critic Care Med. 2007;175:783–790
  27. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250–255
  28. Anderson GP. COPD, asthma and C-reactive protein. Eur Respir J. 2006;27:874–876

PII: S0954-6111(09)00063-8

doi: 10.1016/j.rmed.2009.02.011

Respiratory Medicine
Volume 103, Issue 8 , Pages 1159-1166 , August 2009

Article Tools

* Image Usage & Resolution